TABLE 2.
Baseline Clinical Characteristics (Unweighted)
| All Patients N = 10,863 | Denosumab n = 1,235 | Alendronate n = 5,458 | Ibandronate n = 1,696 | Risedronate n = 1,341 | Raloxifene n = 805 | Teriparatide n = 328 | P Valuea | |
|---|---|---|---|---|---|---|---|---|
| CCI, mean (SD) | 0.8 (1.2) | 1.1 (1.5) | 0.7 (1.2) | 0.7 (1.1) | 0.7 (1.2) | 0.6 (1.1) | 1.1 (1.3) | <0.0001 |
| Number of ICD-9-CM diagnoses,b mean (SD) | 13.3 (8.4) | 16.6 (9.3) | 12.0 (7.8) | 14.3 (8.5) | 13.4 (8.0) | 12.8 (7.6) | 18.5 (10.6) | <0.0001 |
| Number of unique NDCs,c mean (SD) | 16.4 (21.7) | 19.4 (13.9) | 15.7 (12.1) | 16.8 (12.9) | 15.9 (12.4) | 14.0 (11.3) | 22.0 (16.3) | <0.0001 |
| Diagnosis of osteoporosis, n (%) | 3,892 (35.8) | 934 (75.6) | 1,214 (22.2) | 794 (46.8) | 473 (35.3) | 229 (28.4) | 248 (75.6) | <0.0001 |
| Diagnosis of osteopenia, n (%) | 1,251 (11.5) | 49 (4.0) | 656 (12.0) | 193 (11.4) | 218 (16.3) | 124 (15.4) | 11 (3.4) | <0.0001 |
| Osteoporosis therapy, n (%) | 3,166 (29.1) | 675 (54.7) | 1,185 (21.7) | 469 (27.7) | 443 (33.0) | 235 (29.2) | 159 (48.5) | <0.0001 |
| Osteoporosis-related fractures, n (%) | 1,474 (13.6) | 208 (16.8) | 708 (13.0) | 197 (11.6) | 161 (12.0) | 71 (8.8) | 129 (39.3) | <0.0001 |
| Renal insufficiency, n (%) | 431 (4.0) | 86 (7.0) | 216 (4.0) | 47 (2.8) | 46 (3.4) | 19 (2.4) | 17 (5.2) | <0.0001 |
| GI disorders, n (%) | 4,205 (38.7) | 574 (46.5) | 1,887 (34.6) | 716 (42.2) | 553 (41.2) | 309 (38.4) | 166 (50.6) | <0.0001 |
aP values calculated using χ2 tests for categorical variables and analysis of variance for continuous variables across therapies.
bNumber of unique ICD-9-CM diagnosis codes at the 3-digit level on medical claims.
cNumber of unique NDC numbers at the generic level from outpatient pharmacy claims.
CCI = Charlson Comorbidity Index; GI = gastrointestinal; ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification; NDC = National Drug Code; SD = standard deviation.